News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SpineSmith Adds Talented Scientist to Research and Development Team


1/18/2012 10:10:09 AM

AUSTIN, Texas, Jan. 17, 2012 /PRNewswire/ -- SpineSmith, a Celling Biosciences company that designs, develops and markets innovative technologies in the field of regenerative medicine, is pleased to announce the addition of Dr. Matthew Murphy to its team of PhDs.

Dr. Murphy joins SpineSmith in the position of Senior Scientist and will design and implement new strategies for the isolation and application of autologous stem cells for spine, orthopedics, and cardiovascular therapies.

"We are very happy to have Dr. Murphy join our team of PhDs. His expertise in biomaterials and cell technology brings SpineSmith an important opportunity to expand our research especially as we continue to grow as a company," said Vice President of Cell Therapies, Dr. Ted Sand.

Previously, Murphy was a senior researcher at Methodist Hospital Research Institute in Houston, Texas, where he focused on the combination of adult stem cells and biomaterials for regenerative medical applications in orthopedics, spine, pancreatic, and soft tissue repair.

Murphy holds a PhD in Bioengineering from Rice University and a B.S. in Chemical Engineering from The University of Texas at Austin. At Rice, he researched novel biomaterials for bone and cartilage regeneration and developed targeted drug delivery strategies. He also worked at NASA on the design of new spacesuits for travel to the moon and Mars as part of the Constellation Program.

He then joined the laboratory of Dr. Paul Simmons at UT Health Science Center at Houston where he investigated adult stem cells harvested from bone marrow, cortical bone, and adipose tissues. He has authored twelve peer-reviewed publications and two textbook chapters related to tissue engineering and drug delivery.

"I'm excited to help expand Celling Biosciences' therapeutic treatments using adult stem cells," said Dr. Murphy. "Using optimized biomaterials, natural enhancers such as PRP and extracellular matrix proteins, and effective delivery systems, we can maximize stem cell retention and bioactivity. Regenerative therapies are the future and a key to personalized medicine."

About SpineSmith LLC- A Celling Biosciences Company

SpineSmith Partners LP designs, develops and markets implants and biologics for surgical fixation, correction and tissue regeneration of the spine. SpineSmith utilizes a collaborative approach between scientists, engineers and spine surgeons. Our unique approach gives spine surgeons the ability to directly impact the direction of our product portfolio, ensuring applicability and achieving the highest standards of patient care. For more information please visit: www.spinesmithusa.com.

SOURCE SpineSmith LLC


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES